-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

731.P1.39 731. Clinical Autologous Transplantation: Results: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, antibodies, Biological, multiple myeloma, therapy sequence, Lymphoma (any), Diseases, Non-Biological, Hodgkin Lymphoma, Combinations, Elderly, Therapies, Non-Hodgkin Lymphoma, chemotherapy, B-Cell Lymphoma, DLBCL, Plasma Cell Disorders, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant, transplantation, stem cells
Saturday, December 5, 2020: 7:00 AM-3:30 PM

Edwin Burgstaler1*, Luis F. Porrata, MD2, Jeffrey L. Winters, MD3, Eapen K. Jacob, MD4, David J. Inwards, MD2, Stephen M. Ansell, MD, PhD1, Ivana Micallef, MD2, Patrick B. Johnston, MD/ PhD5, Jose C Villasboas, MD2, Jonas Paludo, MD2 and Svetomir N. Markovic, MD, PhD6

1Mayo Clinic, Rochester, MN
2Division of Hematology, Mayo Clinic, Rochester, MN
3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
4Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
5Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
6Division of Medical Oncology, Mayo Clinic, Rochester, MN

Neeraj Saini, MD1, Junsheng Ma, MS2*, Qaiser Bashir, MD3, Ruby Delgado3*, Gabriela Rondon3, Uday R. Popat, MD4, Chitra Hosing, MD3, Yago Nieto, MD3, Partow Kebriaei, MD5, Amin M. Alousi, MD6, Rohtesh S. Mehta, MD, MPH, MS4, Samer A. Srour, MD, MS4, Issa F. Khouri, MD3, Donna M. Weber, MD7, Sheeba K. Thomas, MD8, Hans C. Lee, MD9, Krina K. Patel, M.D.10, Robert Z. Orlowski, MD, PhD7, Richard E. Champlin, MD3 and Muzaffar H. Qazilbash, MD5

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center., Houston, TX
2Department of Statistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
4Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
6Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX
7Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX
9The University of Texas M.D. Anderson Cancer Center, Houston, TX
10Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Christopher Lemieux, MD1, Juliana Craig, BA1*, David Iberri, MD1, Sally Arai, MD, MS1, Laura J. Johnston, MD1, Robert Lowsky, MD, FRCP1, Lori Muffly, MD, MS2, Parveen Shiraz, MD1, Michaela Liedtke, MD3, Andrew R. Rezvani, MD1, Matthew J. Frank, MD, PhD1, Wen-Kai Weng, MD, PhD1, Everett H Meyer, MD, PhD1*, Judith A Shizuru, MD, PhD1, Robert S. Negrin, MD1, David B. Miklos, MD, PhD1 and Surbhi Sidana, MD1

1Stanford University School of Medicine, Stanford, CA
2Assistant Professor of Medicine, Stanford University School of Medicine, Stanford, CA
3Division of Hematology, Stanford University School of Medicine, Stanford, CA

Iuliana Vaxman, MD1,2,3, Alissa Visram, MD4*, Shaji K. Kumar, MD1, Angela Dispenzieri, MD5, Francis K. Buadi, MB, CHB4*, David Dingli, MD, PhD1, Martha Q. Lacy, MD1, Eli Muchtar, MD1*, Prashant Kapoor, MD1, William J Hogan, MB, BCh1, Suzanne R. Hayman, MD4, Nelson Leung, MD1, Wilson I Gonsalves, MD4, Taxiarchis Kourelis, MD1, Rahma M Warsame, MD5, Tamar Berger, MD6,7* and Morie Gertz1

1Mayo Clinic Rochester, Division of Hematology, Rochester, MN
2Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah- Tikva, Israel
3Sackler Faculty of Medicine Tel-Aviv University, Tel-Aviv, Israel
4Division of Hematology, Mayo Clinic, Rochester, MN
5Mayo Clinic, Rochester, MN
6Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
7Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel, Israel

Huimin Liu1*, Wei Liu2*, Ru Li1*, Wenyang Huang3*, Shuhua Yi, MD1*, Ryu Lv1*, Shuhui Deng, MD1*, Gang An1*, Lugui Qiu, MD1 and Dehui Zou, MD1*

1lymphoma and myeloma center, National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood, TIANJIN, China
3National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Thomas Chalopin1*, Nicolas Vallet, MD1*, Marlene Ochmann, MD2*, Mourad Tiab3*, Pascal Godmer4*, Carole Barin5*, Olivier Theisen, MD6*, Olivier Herault, MD, PhD7,8, Emmanuel Gyan, MD, PhD1,7, Lotfi Benboubker, MD1*, Philippe Moreau9,10*, Herve Avet-Loiseau11 and Cyrille Touzeau9,12,13*

1Department of Hematology and Cellular Therapy, Tours University Hospital, UMR CNRS, François Rabelais University, Tours, France
2Hospital of Orleans, Hematology department, Orleans, France
3CH la Roche Sur Yon, La Roche Sur Yon Cedex 9, France
4Clinical Hematology, Centre Hospitalier Bretagne Atlantique, Vannes, France
5Centre Hospitalier universitaire de Tours, Laboratoire de Cytogénétique, Tours, France
6Hematology Biology, Nantes University Hospital, Nantes, France
7CNRS ERL 7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France
8Service d'Hématologie Biologique, Centre Hospitalier Universitaire, Tours, France
9CRCINA, INSERM, CNRS, Angers University and Nantes University, Nantes, France
10Department of Hematology, University Hospital of Nantes, Nantes, France
11Unite de Genomique du Myelome, IUC-T Oncopole, Toulouse, France
12Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD), INCA-DGOS-Inserm 12558, Nantes, France
13Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France

Yago Nieto, MD1, Stephen K. Gruschkus, PhD, MPH2*, Roy B. Jones, MD, PhD1*, Benigno C. Valdez, PhD1, Melissa Timmons, PA-C1*, Chitra Hosing, MD3, Paolo Anderlini1, Partow Kebriaei, MD1, Uday R. Popat, MD1, Muzaffar H. Qazilbash, MD1, Amin M. Alousi, MD4, Samer A. Srour, MD, MS1, Neeraj Saini, MD3, Jeremy Ramdial, MD3, Jin S. Im1, Elizabeth J. Shpall, MD3, Katayoun Rezvani, MD, PhD3, Alison Gulbis5*, Terri Lynn Shigle, PharmD6*, Kris Michael Mahadeo, MD7, Sajad Khazal, MD7, Issa F. Khouri, MD3, Bouthaina S. Dabaja, MD8*, Chelsea C. Pinnix, MD, PhD9*, Jillian R. Gunther, MD, PhD9*, Hun Lee, MD10*, Sairah Ahmed, MD11, Raphael Eric Steiner, MD10, Swaminathan P Iyer, MD12, Ranjit Nair, MD12*, Simrit Parmar, M.D., MSCI13, Branko Cuglievan, MD7*, Farzaneh Maadani, BS, MT1*, Gabriela Rondon3, Richard E. Champlin, MD1 and Borje S. Andersson, M.D., Ph.D.1

1Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
4Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX
5Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
6Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX
7Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
9Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
10Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
11Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX
12Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
13Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Aimaz Afrough, MD1, Leonard C Alsfeld, MD1*, Samer A. Srour, MD, MS2, Qaiser Bashir, MD2, Neeraj Saini, MD2, Chitra Hosing, MD1, Uday R. Popat, MD2, Partow Kebriaei, MD1, Elizabeth J. Shpall, MD1, Ruby Delgado1*, Regan Murphy, PA-C1*, Elisabet E. Manasanch, MD3, Hans C. Lee, MD3, Gregory P. Kaufman, MD3*, Krina K. Patel, M.D.4, Sheeba K. Thomas, MD3, Donna M. Weber, MD3, Robert Z. Orlowski, MD, PhD5, Richard E. Champlin, MD1 and Muzaffar H. Qazilbash, MD1

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX

Shebli Atrash, MD1, Myra Robinson, MSPH2*, Barry Paul, MD, MS3, Sarah Norek, BSN, RN4*, David M Foureau, PhD5, Carrie Ann Syfert, BSN, RN4*, Ami P Ndiaye, NP1*, James T Symanowski, PhD2*, Jordan Robinson1*, Manisha Bhutani, MD6, Peter M. Voorhees, MD1 and Saad Z. Usmani, MD, MBBS, MBA7

1Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
2Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC
3Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC
4Clinical Trials, Levine Cancer Institute, Atrium Health, Charlotte, NC
5Immune Monitoring Core Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, NC
6Levine L. Cancer Institute, Charlotte, NC
7Levine Cancer Institute, Charlotte, NC

Pranav R Santapuram1*, Manali Rupji, MS2*, Michael Graiser, PhD3*, Edmund K. Waller, PhD, MD4, Kristie A. Blum, MD3, Pamela B. Allen, MD, MSc5, Jean L. Koff, MD6, Leonard Heffner, MD7, Mary Jo Lechowicz, MD8, Sagar Lonial, MD9, Jonathan L. Kaufman, MD9, Craig C Hofmeister, MD, MPH3, Madhav V. Dhodapkar, MD10, Ajay Nooka, MD, MPH3, William Blum, MD11, Rebecca B. Klisovic, MD12*, Nisha Joseph, MD3*, Vikas A. Gupta, MD, PhD 13, Amelia Langston, MD9 and Jonathon B. Cohen, MD, MS14

1Internal Medicine, Emory University School of Medicine, Atlanta, GA
2Department of Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlatna, GA
3Winship Cancer Institute, Emory University, Atlanta, GA
4Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
5Winship Cancer Institute, Emory University, Assistant Professor, Department of Hematology and Medical Oncology, Attending Physician, Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Decatur, GA
6Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
7Winship Cancer Institute / Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
8Hematology & Medical oncology, Emory University School of Medicine, Atlanta, GA
9Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
10Emory University School of Medicine, Atlanta, GA
11Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
12Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA
13Winship Cancer Institute/ Hematology and Medical Oncology, Emory University, Atlanta, GA
14Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD4

1City of Hope Medical Center, Duarte, CA
2SWOG Statistical Center, Seattle, WA
3Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Brookfield, WI
4Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX

Abdullah S. Al Saleh, MBBS1, Iuliana Vaxman, MD, BA1*, Harsh Parmar, MD1, M Hasib Sidiqi, MBBS2, Eli Muchtar, MD1*, Francis K. Buadi, MB, CHB1*, David Dingli, MD, PhD1, Martha Q. Lacy, MD1, Rahma M Warsame, MD3, Wilson I Gonsalves, MD1, Taxiarchis Kourelis, MD1, William J Hogan, MB, BCh1, Prashant Kapoor, MD1, Robert Wolf, PharmD, RPh1*, Angela Dispenzieri, MD3, Shaji K. Kumar, MD1 and Morie Gertz1

1Mayo Clinic Rochester, Division of Hematology, Rochester, MN
2Mayo Clinic - Rochester, Perth, WEA, Australia
3Mayo Clinic, Rochester, MN

Kevin Sing, MD1, Roy Sabo, PhD2*, James O'Bryan3*, Matthew Risendal3*, Catherine H Roberts, PhD1* and Amir Ahmed Toor, MD1*

1Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
2Department of Biostatistics, Virginia Commonwealth University, Richmond, VA
3Virginia Commonwealth University, Richmond, VA

*signifies non-member of ASH